Cancer-Fighting viruses take on advanced tumors in early trial

NCT ID NCT07656116

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial tests whether specially designed viruses (VSV-based oncolytic viruses) can safely treat advanced solid tumors that have not responded to standard treatments. The viruses are injected into the body to infect and destroy cancer cells. The study focuses on safety and tolerability, while also monitoring tumor response. About 27 adults with advanced solid tumors will participate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VSV-based recombinant oncolytic viruses
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet established. The viruses may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Hospital Chinese Academy of Medical Scienc
RECRUITING

Langfang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.